🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

Why Veeva Systems (VEEV) Is An Attractive Pick Right Now?

Published 03/28/2019, 09:42 PM
Updated 07/09/2023, 06:31 AM
US500
-
VAR
-
DXCM
-
MASI
-
VEEV
-

Veeva Systems Inc. (NYSE:VEEV) has been investors’ favorite, courtesy of its continued impressive performances. The company benefits from growing demand for cloud-based and vault applications, new product launches, its industry focus approach and international expansion.

Moreover, this Zacks Rank #2 (Buy) stock has an encouraging earnings surprise history, having outpaced the Zacks Consensus Estimate in each of the trailing four quarters, the average being 13.9%. Notably, this trend of consecutive beats underlines its operating efficiency.

In a year’s time, Veeva Systems has rallied 69.9%, outperforming the industry’s 19.3% growth and the S&P 500’s 6.5% gain. With solid prospects, it is an attractive investment pick for investors right now.

What’s Working in Favor?

Veeva Systems’ unique solutions include Veeva Vault, Veeva CRM, Veeva Network and Veeva OpenData. Veeva Vault is the first cloud-based content management system, built specifically for the life sciences. Veeva CRM is a customer relationship management platform that offers cloud-based solutions to reach customers on any channel. Notably, the company has announced mobile innovations in the Veeva CRM platform, which provides information to field teams from any device. Furthermore, New Jersey-based Merck is expanding its use of multichannel Veeva CRM to additional markets, including Latin America and the Asia Pacific.

Another new cloud application of the company is Veeva Vault Training, designed to simplify role-based training across life sciences organizations and help quality teams remain audit-ready and compliant.

Veeva Systems Inc. Price and Consensus

Meanwhile, Veeva Network is a master data management platform that provides global, single-instance customer and product master solution.

For first-quarter fiscal 2020, Veeva Systems expects total revenues between $238 million and $239 million. Adjusted earnings per share are expected between 44 cents and 45 cents. Adjusted operating income is projected in the $85-$86 million band.

For fiscal 2020, revenues are expected between $1.02 billion and $1.03 billion. Adjusted earnings per share are anticipated in the range of $1.91-$1.94 in the same period.

Management expects Subscription revenue growth of 21-22% in fiscal 2020. Commercial Cloud subscription revenues are expected to rise 10%.

Which Way Are Estimates Trending?

The Zacks Consensus Estimate for fiscal 2020 earnings is pegged at 77 cents, reflecting 10% growth year over year. The same for revenues stands at $527 million.

Bottom Line

Veeva Systems seems to be well-positioned for growth on strong guidance and solid product portfolio. The company's long-term earnings growth rate of 14.8% also supports this view.

Other Stocks to Consider

Other top-ranked stocks from the MedTech space are DexCom, Inc. (NASDAQ:DXCM) , Varian Medical Systems, Inc. (NYSE:VAR) and Masimo Corporation (NASDAQ:MASI) , each carrying a Zacks Rank of 2. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

DexCom delivered a positive earnings surprise in each of the trailing four quarters, the average being 132.3%.

Varian Medical has a long-term earnings growth rate of 8%.

Masimo Corporation has a long-term earnings growth rate of 15.6%.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.

This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.

See their latest picks free >>



Veeva Systems Inc. (VEEV): Free Stock Analysis Report

Varian Medical Systems, Inc. (VAR): Free Stock Analysis Report

Masimo Corporation (MASI): Free Stock Analysis Report

DexCom, Inc. (DXCM): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.